Daily Literature Update
2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
Jones DW, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025 Aug 8:S0735-1097(25)06480-0. doi: 10.1016/j.jacc.2025.05.007. Epub ahead of print. PMID: 40815242.
Introduction
Hypertension is a leading cause of cardiovascular disease globally necessitating evidence-based management strategies.
Guideline Development: Joint expert committee report
Key Evidence Base: Landmark randomized controlled trials focused on intensive BP control
Population: Adults at elevated cardiovascular risk without diabetes or prior stroke
Recommendations: Intensive systolic BP target <120 mm Hg to reduce cardiovascular events
- SPRINT trial showed reduced major CV events and mortality with intensive BP control (Wright et al., 2015)
- Long-term SPRINT follow-up confirmed benefits and quantified risks such as hypotension, acute kidney injury (Lewis et al., 2021)
- Guideline recommendations directly informed by this high-quality evidence base
- Evidence gaps remain for excluded populations like diabetes and stroke patients
Context & Related Research
- Jones DW et al., 2025: Comprehensive guideline integrating evidence to optimize BP control with intensive targets (PMID:40815242)
- Wright JT Jr et al., 2015: Landmark RCT showing cardiovascular and mortality benefit from SBP <120 mm Hg (PMID:26551272)
- Lewis CE et al., 2021: Final SPRINT report detailing sustained benefits and adverse event risks with intensive BP lowering (PMID:34010531)
Clinical Implications
- Consider intensive BP control (<120 mm Hg) in selected high-risk adults without diabetes or stroke
- Monitor closely for hypotension and kidney function changes during intensive management
- Individualize therapy balancing cardiovascular benefits and adverse event risks
Strengths & Limitations
| Strengths | Limitations |
|---|---|
| High-quality evidence synthesis from landmark trials | Excludes important patient groups such as those with diabetes or stroke |
| Joint multi-society guideline development | Real-world implementation challenges for intensive targets |
| Clear risk-benefit framework to guide clinical care | Long-term renal safety remains uncertain |
Future Directions
Additional research needed on intensive BP control in excluded populations, long-term renal outcomes, and practical implementation strategies.
Conclusion
The 2025 AHA/ACC guideline endorses intensive blood pressure control grounded in robust evidence, balancing cardiovascular benefits with safety considerations.
Listen to the Podcast
A short discussion of today’s highlight.
